All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ALPHA2: Is ALLO-501A a promising alternative to autologous CAR T-cells?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Frederick Locke, Moffitt Cancer Center, Tampa, US. We asked, Is ALLO-501A a promising alternative to autologous CAR T-cells?

ALPHA2: Is ALLO-501A a promising alternative to autologous CAR T-cells?

ALLO-501A is an off-the-shelf, anti-CD19 allogeneic CAR T-cell therapy which is gene edited to disrupt the TCRα gene to reduce GvHD risk, as well as the CD52 gene to allow the use of ALLO-647, an anti-CD52 mAb, for lymphodepletion without affecting grafted CAR T-cells. Locke evaluates safety and efficacy results from the phase II ALPHA2 trial, investigating ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

 

Share: